Search

Displaying results 371 - 380 of 536 in total
  1. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    [L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment … Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body.

  2. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers.

  3. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.

  4. Indication

    Endometrial Hyperplasia

    go.drugbank.com/conditions/DBCOND0001317
    Drugs: Levonorgestrel · Lynestrenol · Medroxyprogesterone acetate
    Synonyms: Complex endometrial hyperplasia (disorder)
  5. Drug

    Gimeracil

    go.drugbank.com/drugs/DB09257
    ApprovedInvestigational

    Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno".

  6. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

  7. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.

  8. Drug

    Halofuginone

    go.drugbank.com/drugs/DB04866
    InvestigationalVet approved

    Food and Drug Administration in March, 2000.

  9. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.

  10. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.